Jeffrey Wiezorek, SVP Clinical Development at Kite Pharma, Inc. (KITE), sold 9,000 shares at $44.00 ($397K) on 2016-02-16, disclosed to the SEC on 2016-02-18.
Open-market sale of $397k KITE by SVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.00 | 7,612 | $335K | 84.4% |
| 2 | $44.47 | 1,388 | $62K | 15.6% |
| Total | $44.07 avg | 9,000 | $397K | 100% |
| Filing → |
| KITE | SELL | 2017-03-02 | $1.4M | — | Filing → |
| KITE | SELL | 2017-02-06 | $77K | — | Filing → |
| KITE | SELL | 2017-01-10 | $75K | — | Filing → |